This product is mainly indicated for the treatment of depressive disorder. It is a serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressant that acts on 5-hydroxytryptamine (5-HT) transporter and norepinephrine (NE) transporter to inhibit 5-HT and NE reuptake.
This product is indicated for the treatment of depressive disorder and seasonal affective disorder and for the cessation of smoking due to nicotine addiction. In clinical practice, it is also used for the treatment of depressive episodes in bipolar affective disorder (used in combination with mood stabilizers) and attention deficit hyperactivity disorder; it has a certain effect on some sexual dysfunctions.
The efficacy of aripiprazole against schizophrenia has been established in short-term (4-week and 6-week) controlled studies involving schizophrenia patients. Physicians who choose aripiprazole for long-term treatment should regularly re-evaluate its long-term efficacy in individual patients.
Used for treating schizophrenia.
Treatment of schizophrenia: This product is effective for positive symptoms of schizophrenia and also has a certain effect on negative symptoms. It can also alleviate the emotional symptoms associated with schizophrenia, such as depression, anxiety and cognitive deficits. Treatment of depressive episodes in bipolar affective disorder: This product can rapidly control depressive symptoms in bipolar affective disorder. It is effective for both bipolar I and II patients.
< 12 >